ESC 365 - Finerenone use in CKD and T2D: from clinical trials to the clinic.

Open Access

Finerenone use in CKD and T2D: from clinical trials to the clinic.

Session: Cardiorenal benefits of finerenone: protecting the heart and kidneys

Topic: Clinical

Speaker: Doctor P. Taub (La Jolla, US) Professor G. Bakris (Chicago, US)

Sponsored by Bayer

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speakers

Doctor Pam Taub

University of California San Diego, La Jolla (United States of America)

6 presentations

1 follower

Professor George Bakris

University of Chicago Medicine, Chicago (United States of America)

6 presentations

2 followers

4 more presentations in this session

Welcome and introductions.

Speaker: Professor G. Filippatos (Athens, GR) Professor G. Bakris (Chicago, US)

Cardiovascular protection in patients with chronic kidney disease (CKD) and T2D: time for a new approach?

Speaker: Professor J. Bauersachs (Hannover, DE)

Finerenone in cardiovascular care: exploring a new treatment pathway.

Speaker: Professor A. Voors (Groningen, NL)

Q&A and close.

Access the full session

Cardiorenal benefits of finerenone: protecting the heart and kidneys

Speakers: Doctor P. Taub, Professor G. Bakris, Professor G. Filippatos, Professor G. Bakris, Professor J. Bauersachs...

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources